| pubmed-article:3859709 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3859709 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:3859709 | lifeskim:mentions | umls-concept:C0596993 | lld:lifeskim |
| pubmed-article:3859709 | lifeskim:mentions | umls-concept:C0205307 | lld:lifeskim |
| pubmed-article:3859709 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3859709 | lifeskim:mentions | umls-concept:C0163054 | lld:lifeskim |
| pubmed-article:3859709 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:3859709 | pubmed:dateCreated | 1985-8-7 | lld:pubmed |
| pubmed-article:3859709 | pubmed:abstractText | The sensitivity of myeloid progenitor cells from normal subjects (N-CFU-GM) and from leukemic patients in complete remission (LR-CFU-GM) to 4-hydroperoxycyclophosphamide (4-HC) were compared to the sensitivity of leukemic progenitor cells (L-CFU) to this drug. The results were expressed as the dose of 4-HC needed to kill 90% (TD 90) of the progenitor cells. The mean TD 90 were respectively for N-CFU-GM : 59 (+/- 11 S.E.M.) nM ml-1 and for L-CFU 79 (+/- 6 S.E.M.) nM ml-1. Thus, L-CFU were equally sensitive to 4-HC as N-CFU-GM. Moreover, the mean TD 90 for LR-CFU-GM was 87 (+/- 5 S.E.M.) nM ml-1. Thus, the sensitivity of N-CFU-GM and LR-CFU-GM did not differ significantly from that of L-CFU. These results are not encouraging for the use of 4-HC in vitro to eliminate the residual leukemic cells from autologous bone marrow of AML patients in complete remission. The sensitivity of L-CFU was modified neither by previous cytoreductive therapy (different from cyclophosphamide) nor by the time elapsed since diagnosis of AML. | lld:pubmed |
| pubmed-article:3859709 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3859709 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3859709 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3859709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3859709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3859709 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3859709 | pubmed:issn | 0145-2126 | lld:pubmed |
| pubmed-article:3859709 | pubmed:author | pubmed-author:StryckmansPP | lld:pubmed |
| pubmed-article:3859709 | pubmed:author | pubmed-author:LoosMM | lld:pubmed |
| pubmed-article:3859709 | pubmed:author | pubmed-author:DebusscherLL | lld:pubmed |
| pubmed-article:3859709 | pubmed:author | pubmed-author:DelforgeAA | lld:pubmed |
| pubmed-article:3859709 | pubmed:author | pubmed-author:SocquetMM | lld:pubmed |
| pubmed-article:3859709 | pubmed:author | pubmed-author:Rongé-Collard... | lld:pubmed |
| pubmed-article:3859709 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3859709 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:3859709 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3859709 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3859709 | pubmed:pagination | 583-6 | lld:pubmed |
| pubmed-article:3859709 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:meshHeading | pubmed-meshheading:3859709-... | lld:pubmed |
| pubmed-article:3859709 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3859709 | pubmed:articleTitle | Effect of 4-hydroperoxycyclophosphamide on leukemic and normal human myeloid progenitor cells. | lld:pubmed |
| pubmed-article:3859709 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3859709 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
